GLI1, expressed by 76% of lung cancers, can be noncanonically activated by Nrp2/VEGF-mediated MAPK/ERK signaling, and silencing GLI1 attenuates cancer cell stemness and proliferation, and increases their susceptibility to apoptosis [115]. This evidence concerns the gene NRP2 and cancer.